Start-Up Quarterly Statistics, Q4 2014

In Q4 2014 start-ups raised $1.5 billion, a new record. Several companies penned alliances with tech transfer entities; eight start-ups were acquired.

During the final quarter of 2014, start-up companies raised a total of $1.5 billion, a 23% jump from the previous quarter’s record-high $1.2 billion. Q4 2014’s total is now the largest start-up fundraising in a single quarter since this column debuted five years ago. (Three quarters in 2014 have taken the top spot: Q1, Q3, and now Q4.) Biopharma companies pulled in 89% ($1.3 billion), of which nearly half ($551.6 million) was from Series B rounds. Medical device start-ups raised $29 million and in vitro diagnostics companies combined for $137 million; however, $120 million was one Series F financing. (See Exhibit 1.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

Can European Biotech Survive And Thrive In Era Of Instability?

 

Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By 

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

Pfizer CEO Bourla ‘Cautiously Optimistic’ About Tariffs, Pricing Policies

 
• By 

Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.